Lotje Zuur
Bijzonder hoogleraar Keel-, Neus- en Oorheelkunde, in het bijzonder oncologisch translationeel onderzoek
- Naam
- Prof.dr. C.L. Zuur
- Telefoon
- +31 71 526 9111
- c.l.zuur@lumc.nl
- ORCID iD
- null
Bijzonder hoogleraar Keel-, Neus- en Oorheelkunde, in het bijzonder oncologisch translationeel onderzoek
- Faculteit Geneeskunde
- Divisie 3
- Keel-Neus-Oorheelkunde
- Veld, E.A.H.I.; Boere, T.; Zuur, C.L.; Wouters, M.W.; Akkooi, A.C.J. van; Haanen, J.B.A.G.; Crijns, M.B.; Smith, M.J.; Mooyaart, A.; Wakkee, M.; Sewnaik, A.; Strauss, D.C.; Grunhagen, D.J.; Verhoef, C.; Hayes, A.J. & Houdt, W.J. van (2023), ASO Visual Abstract: Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma, Annals of Surgical Oncology 30(9): 5774-5775.
- Boer, F.L.; Ho, V.K.Y.; Louwman, M.W.J.; Schrader, A.M.R.; Zuur, C.L.; Blank, C.U.; Poelgeest, M.I.E. van & Kapiteijn, E.H.W. (2023), Trends in incidence and survival of 1496 patients with mucosal melanoma in the Netherlands (1990-2019), Cancers 15(5).
- Valero, C.; Golkaram, M.; Vos, J.L.; Xu, B.; Fitzgerald, C.; Lee, M.; Kaplan, S.; Han, C.Y.; Pei, X.; Sarkar, R.; Boe, L.A.; Pandey, A.; Koh, E.S.; Zuur, C.L.; Solit, D.B.; Pawlowski, T.; Liu, L.; Ho, A.L.; Chowell, D.; Riaz, N.; Chan, T.A. & Morris, L.G.T. (2023), Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma, The Journal of Clinical Investigation 133(19).
- Vos, J.L.; Burman, B.; Jain, S.; Fitzgerald, C.W.R.; Sherman, E.J.; Dunn, L.A.; Fetten, J.V.; Michel, L.S.; Kriplani, A.; Ng, K.K.; Eng, J.; Tchekmedyian, V.; Haque, S.; Katabi, N.; Kuo, F.S.; Han, C.Y.; Nadeem, Z.; Yang, W.; Makarov, V.; Srivastava, R.M.; Ostrovnaya, I.; Prasad, M.; Zuur, C.L.; Riaz, N.; Pfister, D.G.; Klebanoff, C.A.; Chan, T.A.; Ho, A.L. & Morris, L.G.T. (2023), Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial, Nature Medicine.
- Zijlker, L.P.; Burg, S.J.C. van der; Blank, C.U.; Zuur, C.L.; Klop, W.M.C.; Wouters, M.W.M.J.; Houdt, W.J. van & Akkooi, A.C.J. van (2023), Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery, European Journal of Cancer 185: 131-138.
- Geer, A.F. de; Koning, S.G.B. de; Alphen, M.J.A. van; Mierden, S. van der; Zuur, C.L.; Leeuwen, F.W.B. van; Loeve, A.J.; Veen, R.L.P. van & Karakullukcu, M.B. (2022), Registration methods for surgical navigation of the mandible: a systematic review, International Journal of Oral and Maxillofacial Surgery 51(10): 1318-1329.
- Vos, J.L.; Zuur, C.L.; Smit, L.A.; Boer, J.P. de; Al-Mamgani, A.; Brekel, M.W.M. van den; Haanen, J.B.A.G. & Vogel, W.V. (2022), [18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma, European Journal of Nuclear Medicine and Molecular Imaging 49(6): 2010-2022.
- Reijers, I.L.M.; Rawson, R.V.; Colebatch, A.J.; Rozeman, E.A.; Menzies, A.M.; Akkooi, A.C.J. van; Shannon, K.F.; Wouters, M.W.; Saw, R.P.M.; Houdt, W.J. van; Zuur, C.L.; Nieweg, O.E.; Ch'ng, S.; Klop, W.M.C.; Spillane, A.J.; Long, G.V.; Scolyer, R.A.; Wiel, B.A. van de & Blank, C.U. (2022), Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma, JAMA Surgery 157(4): 335-342.
- Hulst, H.J. van der; Vos, J.L.; Tissier, R.; Smit, L.A.; Martens, R.M.; Beets-Tan, R.G.H.; Brekel, M.W.M. van den; Zuur, C.L. & Castelijns, J.A. (2022), Quantitative Diffusion-Weighted Imaging Analyses to Predict Response to Neoadjuvant Immunotherapy in Patients with Locally Advanced Head and Neck Carcinoma, Cancers 14(24).
- Reijers, I.L.M.; Menzies, A.M.; Akkooi, A.C.J. van; Versluis, J.M.; Heuvel, N.M.J. van den; Saw, R.P.M.; Pennington, T.E.; Kapiteijn, E.; Veldt, A.A.M. van der; Suijkerbuijk, K.P.M.; Hospers, G.A.P.; Rozeman, E.A.; Klop, W.M.C.; Houdt, W.J. van; Sikorska, K.; Hage, J.A. van der; Grunhagen, D.J.; Wouters, M.W.; Witkamp, A.J.; Zuur, C.L.; Lijnsvelt, J.M.; Acosta, A.T.; Grijpink-Ongering, L.G.; Gonzalez, M.; Jozwiak, K.; Bierman, C.; Shannon, K.F.; Ch'ng, S.; Colebatch, A.J.; Spillane, A.J.; Haanen, J.B.A.G.; Rawson, R.V.; Wiel, B.A. van de; Poll-franse, L.V. van de; Scolyer, R.A.; Boekhout, A.H.; Long, G.V. & Blank, C.U. (2022), Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma, Nature Medicine 28(6): 1178-+.
- Diepstraten, F.A.; Wiersma, J.; Schoot, R.A.; Knops, R.R.G.; Zuur, C.L.; Meijer, A.J.M.; Fajardo, R.D.; Pieters, B.R.; Balgobind, B.V.; Westerveld, H.; Freling, N.; Tinteren, H. van; Smeele, L.E.; Bel, A.; Heuvel-eibrink, M.M. van den; Stokroos, R.J.; Merks, J.H.M.; Hoetink, A.E. & Hol, M.L.F. (2022), Patterns of hearing loss in Irradiated survivors of head and neck rhabdomyosarcoma, Cancers 14(23).
- Akkooi, A.C.J. van; Hieken, T.J.; Burton, E.M.; Ariyan, C.; Ascierto, P.A.; Asero, S.V.M.A.; Blank, C.U.; Block, M.S.; Boland, G.M.; Caraco, C.; Chng, S.; Davidson, B.S.; Neto, J.P.D.; Faries, M.B.; Gershenwald, J.E.; Grunhagen, D.J.; Gyorki, D.E.; Han, D.L.; Hayes, A.J.; Houdt, W.J. van; Karakousis, G.C.; Klop, W.M.C.; Long, G.V.; Lowe, M.C.; Menzies, A.M.; Bagge, R.O.; Pennington, T.E.; Rutkowski, P.; Saw, R.P.M.; Scolyer, R.A.; Shannon, K.F.; Sondak, V.K.; Tawbi, H.; Testori, A.A.E.; Tetzlaff, M.T.; Thompson, J.F.; Zager, J.S.; Zuur, C.L.; Wargo, J.A.; Spillane, A.J.; Ross, M.I. & Int Neoadjuvant Melanoma Consortiu (2022), Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC) (Jan, 10.1245/S10434-021-11236-Y, 2022), Annals of Surgical Oncology 29(8): 5241-5242.
- Zijlker, L.P.; Bakker, M.; Hiel, B. van der; Bruining, A.; Klop, W.M.C.; Zuur, C.L.; Wouters, M.W.J.M. & Akkooi, A.C.J. van (2022), Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinoma, Journal of Surgical Oncology.
- Geer, A.F. de; Alphen, M.J.A. van; Zuur, C.L.; Loeve, A.J.; Veen, R.L.P. van & Karakullukcu, M.B. (2022), A hybrid registration method using the mandibular bone surface for electromagnetic navigation in mandibular surgery, International Journal of Computer Assisted Radiology and Surgery 17(7): 1343-1353.
- (2022), MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma, Immuno-Oncology and Technology 15.
- Vos, J.L.; Zuur, C.L.; Smit, L.A.; Boer, J.P. de; Al-Mamgani, A.; Brekel, M.W.M. van den; Haanen, J.B.A.G. & Vogel, W.V. (2021), [F-18]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma, European Journal of Nuclear Medicine and Molecular Imaging.
- Vos, J.L.; Elbers, J.B.W.; Krijgsman, O.; Traets, J.J.H.; Qiao, X.H.; Leun, A.M. van der; Lubeck, Y.; Seignette, I.M.; Smit, L.A.; Willems, S.M.; Brekel, M.W.M. van den; Dirven, R.; Karakullukcu, M.B.; Karssemakers, L.; Klop, W.M.C.; Lohuis, P.J.F.M.; Schreuder, W.H.; Smeele, L.E.; Velden, L.A. van der; Tan, B.; Onderwater, S.; Jasperse, B.; Vogel, W.V.; Al-Mamgani, A.; Keijser, A.; Noort, V. van der; Broeks, A.; Hooijberg, E.; Peeper, D.S.; Schumacher, T.N.; Blank, C.U.; Boer, J.P. de; Haanen, J.B.A.G. & Zuur, C.L. (2021), Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma, Nature Communications 12(1).
- Al-Mamgani, A.; Kessels, R.; Navran, A.; Hamming-Vrieze, O.; Zuur, C.L.; Boer, J.P. de; Jonker, M.C.J.; Janssen, T.; Sonke, J.J. & Marijnen, C.A.M. (2021), Reduction of GTV to high-risk CTV radiation margin in head and neck squamous cell carcinoma significantly reduced acute and late radiation-related toxicity with comparable outcomes, Radiotherapy & Oncology 162: 170-177.
- Duinkerken, C.W.; Weger, V.A. de; Dreschler, W.A.; Molen, L. van der; Pluim, D.; Rosing, H.; Nuijen, B.; Hauptmann, M.; Beijnen, J.H.; Balm, A.J.M.; Boer, J.P. de; Burgers, J.A.; Marchetti, S.; Schellens, J.H.M. & Zuur, C.L. (2021), Transtympanic sodium thiosulfate for prevention of cisplatin-induced ototoxicity, Otology and Neurotology 42(5): 678-685.
- Duinkerken, C.W.; Rohaan, F.W.; Weger, V.A. de; Lohuis, P.J.F.M.; Latenstein, M.N.; Theunissen, E.A.R.; Balm, A.J.M.; Dreschler, W.A.; Haanen, J.B.A.G. & Zuur, C.L. (2019), Sensorineural hearing loss after adoptive cell immunotherapy for melanoma using MART-1 specific T cells, Otology and Neurotology 40(7).